



HAL
open science

Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score

Minh-Phuong Huynh-Le, Roshan Karunamuni, Chun Chieh Fan, Lui Asona, Wesley Thompson, Maria Elena Martinez, Rosalind Eeles, Zsofia Kote-Jarai, Kenneth Muir, Artitaya Lophatananon, et al.

► To cite this version:

Minh-Phuong Huynh-Le, Roshan Karunamuni, Chun Chieh Fan, Lui Asona, Wesley Thompson, et al.. Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score. *Prostate Cancer and Prostatic Diseases*, 2022, 25 (4), pp.755-761. 10.1038/s41391-022-00497-7. hal-04204681

HAL Id: hal-04204681

<https://univ-rennes.hal.science/hal-04204681>

Submitted on 29 Jan 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution 4.0 International License

ARTICLE OPEN



Clinical Research

Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score

Minh-Phuong Huynh-Le ^{1,2,3}, Roshan Karunamuni^{2,3}, Chun Chieh Fan ³, Lui Asona ², Wesley K. Thompson^{4,5}, Maria Elena Martinez⁶, Rosalind A. Eeles ^{7,8}, Zsofia Kote-Jarai⁷, Kenneth R. Muir ⁹, Artitaya Lophatananon⁹, Johanna Schleutker ^{10,11}, Nora Pashayan ^{12,13}, Jyotsna Batra ^{14,15}, Henrik Grönberg ¹⁶, David E. Neal^{17,18,19}, Børge G. Nordestgaard ^{20,21}, Catherine M. Tangen²², Robert J. MacInnis^{23,24}, Alicja Wolk ²⁵, Demetrius Albanes²⁶, Christopher A. Haiman²⁷, Ruth C. Travis ²⁸, William J. Blot^{29,30}, Janet L. Stanford^{31,32}, Lorelei A. Mucci³³, Catharine M. L. West ³⁴, Sune F. Nielsen^{21,20}, Adam S. Kibel³⁵, Olivier Cussenot^{36,37}, Sonja I. Berndt²⁶, Stella Koutros²⁶, Karina Dalsgaard Sørensen ^{38,39}, Cezary Cybulski⁴⁰, Eli Marie Grindedal⁴¹, Florence Menegaux ⁴², Jong Y. Park ⁴³, Sue A. Ingles⁴⁴, Christiane Maier⁴⁵, Robert J. Hamilton^{46,47}, Barry S. Rosenstein⁴⁸, Yong-Jie Lu ⁴⁹, Stephen Watya⁵⁰, Ana Vega ^{51,52,53}, Manolis Kogevinas ^{54,55,56}, Fredrik Wiklund ¹⁶, Kathryn L. Penney⁵⁷, Chad D. Huff⁵⁸, Manuel R. Teixeira ^{59,60,61}, Luc Multigner ⁶², Robin J. Leach⁶³, Hermann Brenner ^{64,65,66}, Esther M. John⁶⁷, Radka Kaneva⁶⁸, Christopher J. Logothetis⁶⁹, Susan L. Neuhausen⁷⁰, Kim De Ruyck⁷¹, Piet Ost ⁷², Azad Razack⁷³, Lisa F. Newcomb^{31,74}, Jay H. Fowke ⁷⁵, Marija Gamulin ⁷⁶, Aswin Abraham ⁷⁷, Frank Claessens⁷⁸, Jose Esteban Castelao⁷⁹, Paul A. Townsend^{80,81}, Dana C. Crawford ⁸², Gyorgy Petrovics ^{83,84}, Ron H. N. van Schaik⁸⁵, Marie-Élise Parent ^{86,87}, Jennifer J. Hu⁸⁸, Wei Zheng ²⁹, UKGPCS collaborators⁹³, APCB (Australian Prostate Cancer BioResource)^{94,95}, NC-LA PCaP Investigators⁹⁶, The IMPACT Study Steering Committee and Collaborators⁹⁷, Canary PASS Investigators^{31,74}, The Profile Study Steering Committee⁹⁸, and The PRACTICAL Consortium, Ian G. Mills⁸⁹, Ole A. Andreassen⁹⁰, Anders M. Dale^{91,3,90} and Tyler M. Seibert

© The Author(s) 2022

BACKGROUND: Prostate cancer risk stratification using single-nucleotide polymorphisms (SNPs) demonstrates considerable promise in men of European, Asian, and African genetic ancestries, but there is still need for increased accuracy. We evaluated whether including additional SNPs in a prostate cancer polygenic hazard score (PHS) would improve associations with clinically significant prostate cancer in multi-ancestry datasets.

METHODS: In total, 299 SNPs previously associated with prostate cancer were evaluated for inclusion in a new PHS, using a LASSO-regularized Cox proportional hazards model in a training dataset of 72,181 men from the PRACTICAL Consortium. The PHS model was evaluated in four testing datasets: African ancestry, Asian ancestry, and two of European Ancestry—the Cohort of Swedish Men (COSM) and the ProtecT study. Hazard ratios (HRs) were estimated to compare men with high versus low PHS for association with clinically significant, with any, and with fatal prostate cancer. The impact of genetic risk stratification on the positive predictive value (PPV) of PSA testing for clinically significant prostate cancer was also measured.

RESULTS: The final model (PHS290) had 290 SNPs with non-zero coefficients. Comparing, for example, the highest and lowest quintiles of PHS290, the hazard ratios (HRs) for clinically significant prostate cancer were 13.73 [95% CI: 12.43–15.16] in ProtecT, 7.07 [6.58–7.60] in African ancestry, 10.31 [9.58–11.11] in Asian ancestry, and 11.18 [10.34–12.09] in COSM. Similar results were seen for association with any and fatal prostate cancer. Without PHS stratification, the PPV of PSA testing for clinically significant prostate cancer in ProtecT was 0.12 (0.11–0.14). For the top 20% and top 5% of PHS290, the PPV of PSA testing was 0.19 (0.15–0.22) and 0.26 (0.19–0.33), respectively.

CONCLUSIONS: We demonstrate better genetic risk stratification for clinically significant prostate cancer than prior versions of PHS in multi-ancestry datasets. This is promising for implementing precision-medicine approaches to prostate cancer screening decisions in diverse populations.

Prostate Cancer and Prostatic Diseases (2022) 25:755–761; <https://doi.org/10.1038/s41391-022-00497-7>

INTRODUCTION

Identification of men at greatest risk of developing prostate cancer remains an important challenge. Risk stratification using common genetic markers, such as single-nucleotide polymorphisms (SNPs),

shows promise toward more effectively identifying men at greatest risk of developing aggressive or fatal prostate cancer [1, 2]. Analyses of benefit, harm, and cost-effectiveness support use of genomic risk stratification to guide prostate cancer

A full list of authors and their affiliations appears at the end of the paper.

Received: 21 September 2021 Accepted: 12 January 2022

Published online: 12 February 2022

screening [3, 4]. Ensuring these tools perform well in diverse populations is important to ensure risk stratification is optimal for all men and avoid exacerbating existing health disparities [5, 6].

We previously developed a polygenic hazard score (PHS) and demonstrated in an independent European dataset that the PHS was associated with age at diagnosis of clinically significant prostate cancer [1]. Risk stratification with this score also improved the accuracy of PSA testing [7, 8]. We then validated the PHS model (with 46 SNPs) for association with age at diagnosis and with prostate-cancer specific mortality in a dataset that included men of diverse descent, including European, African, and Asian ancestry [2]. We have also improved performance in men of African ancestry by searching for SNPs within that subpopulation [9, 10].

Recent meta-analyses have identified over 200 SNPs associated with prostate cancer, including some identified through subset analyses in men of non-European ancestry [11, 12]. Given the increasing number of SNPs associated with prostate cancer, we evaluated whether including more SNPs in a prostate cancer PHS would improve associations with clinically significant prostate cancer in multi-ancestry datasets.

METHODS

Participants

Genotype and phenotype data, all de-identified, were obtained from the PRACTICAL consortium. Participants had previously been genotyped via the OncoArray [13] or the iCOGs [14] chips; 90,638 men were available for this analysis.

The available data were split into a training dataset and four testing datasets, taking into account prior power analyses and PHS association results [7, 15, 16]. The training dataset for the model included 72,181 men of European genetic ancestry genotyped via OncoArray (24,010 controls and 48,171 cases). The four testing datasets included: (1) men of African ancestry ($n = 6253$: 3013 controls and 3240 cases), (2) men of Asian ancestry ($n = 2378$: 1184 controls and 1194 cases), (3) the Cohort of Swedish Men (COSM) population-based cohort with long-term outcomes [17] ($n = 3279$: 1116 controls, 2163 cases, and 278 prostate cancer deaths), and (4) the ProtecT population-based prospective trial with screening (prostate-specific antigen, PSA) and biopsy outcomes for both cases and controls ($n = 6411$: 4828 controls and 1583 cases) [18].

Polygenic hazard score model development using LASSO regularization

We sought to develop an optimal, integrated PHS model with candidate SNPs chosen from those used in the prior PHS and from those identified as susceptibility loci for prostate cancer in a genome-wide trans-ancestry meta-analysis [11]. Candidate SNPs included the 46 from the original PHS development and 269 from the meta-analysis. A machine-learning, LASSO-regularized Cox proportional hazards model approach was used to objectively select SNPs and estimate weights, as described previously [8].

There were 299 unique candidate SNPs associated with prostate cancer consistent across the training and testing datasets used in the present work. We first identified SNP pairs (among the 299 candidates) that were highly correlated ($r^2 > 0.95$). Each of these paired, correlated SNPs was tested in a univariable Cox proportional hazards model for association with age at prostate cancer diagnosis; the SNP with the larger p -value was eliminated from inclusion in the model. All other (unpaired) SNPs were included as candidates for the present PHS model.

The R (version 4.0.1) “glmnet” package was used to estimate the LASSO-regularized Cox proportional hazards model [19, 20]. Age at prostate cancer diagnosis was the time to event, and the predictor variables included the genotype allele counts of candidate SNPs and first four European ancestry principal components. Controls were censored at age of last follow-up. The LASSO-regularized model’s hyper-parameter (λ) was selected using 10-fold cross-validation [19, 20]. The final form of the LASSO model was estimated using the λ value that minimized the mean cross-validated error.

Association with prostate cancer

We evaluated the association of the adapted PHS with clinically significant prostate cancer, as well as any prostate cancer, via Cox proportional

hazards models in each of the four testing datasets. Clinically significant prostate cancer was defined to be a prostate cancer case with Gleason score ≥ 7 , PSA ≥ 10 ng/mL, T3-T4 stage, nodal metastases, or distant metastases [21].

As the COSM dataset had long-term follow-up data available [17], we additionally evaluated the adapted PHS for association with age at prostate cancer death [16]. There were 278 deaths from prostate cancer in the COSM dataset.

Hazard ratio performance

Hazard ratios between the top 5% and middle 40% ($HR_{95/50}$), top 20% and middle 40% ($HR_{80/50}$), bottom 20% and middle 40% ($HR_{20/50}$), and top and bottom 20% ($HR_{80/20}$) were estimated for any, for clinically significant, and for fatal prostate cancer. Percentiles of genetic risk were determined within the controls the training set with age less than 70 years [1, 2, 7, 8].

Family history

Given that family history of prostate cancer is currently one of the most useful clinical risk factors for the development of prostate cancer, we used Cox proportional hazards models to assess family history for association with any, with clinically significant, or with fatal prostate cancer. Family history of prostate cancer was defined as presence or absence of a first-degree relative diagnosed with prostate cancer. Multivariable models using both family history and the adapted PHS were compared to using family history alone via a log-likelihood test with $\alpha = 0.01$. HRs were calculated for each variable: HRs for PHS in the multivariable models were estimated as the $HR_{80/20}$ in each testing dataset (e.g., men in the highest vs. lowest quintile of genetic risk by PHS). HRs for family history of prostate cancer were estimated as the exponent of the beta from the multivariable Cox regression. As done previously [1, 7], p -values were truncated at $< 10^{-16}$.

Positive predictive value performance

Positive predictive value (PPV) performance of PSA testing was calculated using data from the population-based ProtecT screening study [18] (prostate biopsy results were available for both cases and controls with a positive PSA [≥ 3 ng/mL]). To estimate the PPV and confidence intervals, we generated 1000 bootstrap samples using ProtecT participants with positive PSA, while maintaining the 1:2 case:control ratio in the ProtecT dataset. PPV was calculated as the proportion of PSA-positive participants who were diagnosed with clinically significant prostate cancer on biopsy, looking at those participants in the top 5 (PPV_{95}) or top 20 percentiles (PPV_{80}) of PHS genetic risk.

Cumulative incidence curves for PHS

Genetic-risk-stratified cumulative incidence curves for prostate cancer were derived using previously described methods [7, 8]. Briefly, age-specific population data from the United Kingdom (Cancer Research UK [7]) were used to estimate prostate cancer incidence for men aged 40–70 years. Data from the population-based Cluster Randomized Trial of PSA Testing for Prostate Cancer (CAP) trial [7] were used to adjust this population incidence curve to reflect the age-specific cumulative incidence of clinically significant and non-clinically-significant prostate cancer. Genetic-risk-stratified cumulative incidence curves were then calculated for men in the upper 5 and 20 percentiles of PHS genetic risk by multiplying the prostate-cancer-specific cumulative incidence by the mean value of $HR_{95/50}$ and $HR_{80/50}$ in the testing dataset, respectively.

RESULTS

A total of 290 SNPs returned non-zero SNP coefficients using the regularization-weight selection and were included in the final model, called PHS290 (Supplementary Material).

HR performance of PHS290 demonstrates risk stratification across percentiles of genetic risk (Table 1). Comparing the top and bottom quintiles of genetic risk for clinically significant prostate cancer, men with high PHS had HRs of 13.73 [12.43–15.16], 7.07 [6.58–7.60], 10.31 [9.58–11.11], and 11.18 [10.34–12.09] in the ProtecT, African, Asian, and COSM datasets, respectively. Similar risk stratification was seen when evaluating risk of any prostate cancer. Finally, when comparing the top and bottom quintiles of

Table 1. Hazard ratio (HR) performance in the four testing datasets.

Dataset	Prostate cancer type	HRs and 95% CI			
		HR _{20/50}	HR _{80/50}	HR _{95/50}	HR _{80/20}
ProtecT <i>n</i> = 6411	Any	0.31 [0.30–0.32]	3.47 [3.36–3.58]	5.93 [5.67–6.21]	11.16 [10.48–11.88]
	Clinically significant	0.28 [0.27–0.30]	3.86 [3.67–4.06]	6.91 [6.42–7.44]	13.73 [12.43–15.16]
African <i>n</i> = 6253	Any	0.43 [0.42–0.45]	2.58 [2.50–2.67]	3.69 [3.52–3.86]	5.95 [5.59–6.34]
	Clinically significant	0.40 [0.39–0.41]	2.82 [2.72–2.93]	4.33 [4.10–4.57]	7.07 [6.58–7.60]
Asian <i>n</i> = 2378	Any	0.34 [0.33–0.35]	2.99 [2.89–3.08]	5.08 [4.85–5.33]	8.75 [8.21–9.32]
	Clinically significant	0.31 [0.30–0.33]	3.24 [3.12–3.36]	5.66 [5.46–5.98]	10.31 [9.58–11.11]
COSM <i>n</i> = 3279	Any	0.33 [0.32–0.34]	3.54 [3.42–3.65]	5.77 [5.51–6.04]	10.87 [10.21–11.57]
	Clinically significant	0.32 [0.31–0.33]	3.59 [3.45–3.75]	5.91 [5.58–6.26]	11.18 [10.34–12.09]
	Fatal	0.38 [0.35–0.42]	2.95 [2.68–3.25]	4.49 [3.93–5.13]	7.73 [6.45–9.27]

HRs are shown with mean sample-weight-corrected values and 95% confidence intervals. Calculations were done using age at diagnosis of any or of clinically significant prostate cancer across all datasets, respectively, and also with age at prostate cancer death for the COSM dataset.

Table 2. Multivariable Cox models with both PHS and family history of prostate cancer (defined as ≥ 1 first-degree relative affected) for association with any prostate cancer, with clinically significant prostate cancer, and with fatal prostate cancer.

Dataset	Variable	Any prostate cancer			
		beta	z-score	p-value	HR
ProtecT (iCOGs), <i>n</i> = 5703	PHS	2.11	72.1	$< 10^{-16}$	8.13
	Family history	0.06	1.7	0.1	1.07
African (OncoArray), <i>n</i> = 5557	PHS	1.64	53.8	$< 10^{-16}$	5.03
	Family history	1.13	46.6	$< 10^{-16}$	3.09
Asian (OncoArray); <i>n</i> = 1028	PHS	1.99	68.5	$< 10^{-16}$	7.64
	Family history	0.45	13.1	$< 10^{-16}$	1.56
COSM (OncoArray), <i>n</i> = 2453	PHS	2.13	71.2	$< 10^{-16}$	8.71
	Family history	0.53	19.0	$< 10^{-16}$	1.70
Dataset	Variable	Clinically significant prostate cancer			
		beta	z-score	p-value	HR
ProtecT (iCOGs), <i>n</i> = 5703	PHS	2.32	49.8	$< 10^{-16}$	10.01
	Family history	-0.01	-0.2	0.82	0.99
African (OncoArray), <i>n</i> = 5557	PHS	1.67	37.4	$< 10^{-16}$	5.19
	Family history	1.17	33.2	$< 10^{-16}$	3.22
Asian (OncoArray), <i>n</i> = 1028	PHS	1.89	50.4	$< 10^{-16}$	6.90
	Family history	0.13	2.5	0.012	1.14
COSM (OncoArray), <i>n</i> = 2453	PHS	2.13	56.9	$< 10^{-16}$	6.90
	Family history	0.45	12.6	$< 10^{-16}$	1.57
Dataset	Variable	Fatal prostate cancer			
		beta	z-score	p-value	HR
COSM (OncoArray), <i>n</i> = 2453	PHS	1.68	19.8	$< 10^{-16}$	5.51
	Family history	0.43	5.0	4.7×10^{-7}	1.53

Analyses were limited to participants with known family history. Beta and z-scores refer to the overall association (within the multivariable Cox regression) with the endpoint of interest, within the corresponding testing dataset. The *p*-values reported are two-tailed from the multivariable Cox models.

genetic risk in the COSM dataset, men with high PHS had a HR of 7.73 [6.45–9.27] for prostate cancer death.

Family history and PHS290

Family history data based on self-report and were available for 89%, 89%, 43%, and 75% of individuals in the ProtecT, African, Asian, and COSM datasets, respectively; 7%, 18%, 9%, and 14% of individuals, respectively, reported having a first-degree relative diagnosed with prostate cancer. The combination of family history and PHS performed better than family history, alone, for clinically significant prostate cancer (and for any prostate cancer) in each of

the four testing datasets (log-likelihood $p < 10^{-16}$; Table 2). Additionally, family history and PHS together performed better than family history, alone, for fatal prostate cancer in the COSM dataset (log-likelihood $p < 10^{-16}$).

Positive predictive value performance of PHS290

The PPV of PSA testing for clinically significant prostate cancer was 0.19 (0.15–0.22) for the top 20% of genetic risk (PPV₈₀) and 0.26 (0.19–0.33) for the top 5% of genetic risk (PPV₈₀; Fig. 1). Both were greater than the overall PPV of PSA alone, which was 0.12 (0.11–0.14).




Fig. 1 PPV performance in the ProtecT dataset for clinically significant prostate cancer, estimated using 3 approaches: standard (not using PHS), top 20% of PHS values (PPV80), and top 5% of PHS values (PPV95). Error bars are 95% bootstrap confidence intervals.

Cumulative incidence curves for PHS290

Genetic-risk-stratified cumulative incidence curves for clinically significant and non-clinically significant prostate cancer demonstrate greater prostate cancer incidence with higher genetic-adjusted risk (Fig. 2).

DISCUSSION

The improved PHS (PHS290) demonstrates excellent genetic risk stratification, including for clinically significant prostate cancer. This was true in four separate testing sets of varied genetic ancestry (Asian, African, European). Additionally, PHS290 was associated with lifetime prostate-cancer-specific mortality in a population-based cohort [16]. Hazard ratios with PHS290 are larger for each of these associations than those reported for previous versions of PHS [2, 8], demonstrating the value of incorporating SNPs from genome-wide meta-analysis and fine-mapping. The improvements demonstrated here are promising for implementing personalized approaches to prostate cancer screening decisions in diverse populations.

Health disparities are a major problem in prostate cancer. Given the exclusion of non-European data in most genome studies [5, 22–24], it is important that the pool of candidate SNPs here included those identified from a recent trans-ancestry meta-analysis [11]. Testing and improving performance of genomic risk scores in diverse populations is critical to equitable implementation of these new tools and important for avoiding exacerbation of existing disparities. PHS290 still performs better in men of European genetic ancestry—an expected result, given the much greater data availability in that population. Further genomic studies in diverse populations are essential, as diversity in model development improves performance in diverse populations [9, 10].

The intersection of social constructs like race/ethnicity and genomics also raises interesting and entangled challenges. Even availability of genomic data is only part of the problem, as disparities in health outcomes are rooted in systemic racism and inequities in access to healthcare [25, 26]. Genotypic ancestry may be a step toward biology, but the continental groups still represent an oversimplification of genetic diversity and a pre-determined assumption that socially defined categories have biological meaning in all contexts. We have previously shown that agnostic genetic




Fig. 2 Genetic-risk-adjusted cumulative incidence curves for PHS290. Curves are shown for the upper 5th (>95th) and upper 20th (>80th) percentile of PHS290 for clinically significant and non-clinically-significant prostate cancer. The reference curves represent the overall population average from the UK.

clusters are informative for subgroup analyses [2], and this approach may be a better way forward, provided the genomic diversity of the whole population is represented in the available data. Here, we have used genotypic ancestry to evaluate the potential differential performance in groups historically excluded from large-scale genomic studies. We also note that local ancestry may be a critical consideration in admixed populations. We have found previously that PHS performance can vary by the makeup of a *region* of the genome, beyond what is explained by *global* ancestry categories assigned for an individual's entire genome [10]. Despite these challenges and opportunities for future improvement, the current results demonstrate PHS290 does provide meaningful risk stratification in diverse datasets.

The cumulative incidence of clinically significant prostate cancer is heavily influenced by age-specific genetic risk, as demonstrated by genetic-risk-stratified cumulative incidence curves (Fig. 2). As men with high PHS290 age, the incidence curve for clinically significant prostate cancer increases dramatically, prominently separating from the incidence for non-clinically-significant prostate cancer. This effect is driven by the high HR for clinically significant prostate cancer in these men, combined with increasing incidence specifically of more clinically significant cancers as men age [7, 27]. Furthermore, we found that risk stratification with PHS290 improved accuracy of PSA testing, as assessed by probability of a positive PSA test leading to a diagnosis of clinically significant cancer on biopsy. Consistent with a prior study [8], this improvement in PPV of PSA testing was not better when using PHS290 than when using PHS46 in this dataset [2]. PPV analyses in larger datasets could permit finer granularity for age-specific genetic risk to assess whether the increased HRs of PHS290 might translate to better performance of PSA testing than that achieved already with PHS46.

The HRs reported here suggest clinical relevance for PHS290. Predictive tools in routine clinical use for other diseases (e.g., breast cancer, diabetes, and cardiovascular disease) have reported HRs of ~1–3 for endpoints of interest [28–31]. Current guidelines recommend earlier and more frequent consideration of prostate cancer screening for men with a family history of prostate cancer or African ancestry, citing an elevated risk 28–80% above that of men without these risk factors [32–34]. Guidelines more strongly recommend earlier and more frequent screening in men with germline mutations in *BRCA2*, which are rare but are estimated to infer up to 3-fold

increased risk [33–35]. In the present study, men in the top 20% for PHS290 (compared to men with *average* risk) had HRs for clinically significant prostate cancer of ~2.8–3.9. For men in the top 5% for PHS290, those HRs increase to 4.3–6.9, depending on ancestry. While individuals with high polygenic risk may also develop low-grade prostate cancer in their lifetime, the time-to-event analysis applied here shows that high genetic risk confers a greater hazard for prostate cancer death. This finding is consistent with prior reports, though the effect size is larger with PHS290 [2, 16, 33].

Family history data were not uniformly available across source studies or testing datasets and were notably less available in the Asian dataset (43%, compared to $\geq 75\%$ in the other testing datasets). The proportion of individuals with positive family history—among those with available family history data—also varied across datasets, ranging from 7% (ProtecT) to 18% (African). The interplay of family history and polygenic risk warrants further investigation in more complete cohorts. It is also worth noting that family history availability is not always available (or reliable) in clinical practice. Nonetheless, both family history and polygenic risk appear important for assessing individual risk of prostate cancer. Possibly, family history represents not only inherited genetic risk but also shared environmental exposures.

If this technology is to be implemented in clinical practice, it is important to consider reliability. Genotype arrays are known to have excellent reproducibility, with concordance of 99.40–99.87% on repeat testing with the same array [36]. Concordance across genotyping platforms is also excellent at 98.80% [36].

Our work has some limitations. First, the weights were calculated in men of European genetic ancestry alone, although SNP candidate selection was performed in multi-ancestry analyses. Future studies evaluating PHS for prostate cancer risk stratification will include non-Europeans in SNP weight calculations. The available data did not permit testing of PPV or association with fatal disease in non-European populations. Moreover, the cumulative incidence curves here are specific to the UK, where we had the most robust population age-specific incidence data for clinically significant prostate cancer. The testing sets used in the present study did represent a very small proportion of the data used for candidate SNP identification in the prior genome-wide association meta-analysis (as opposed to the development of PHS46, which was performed in a dataset completely independent of the validation dataset) [2, 11]. However, the training and testing sets were kept separate in the present study, and the use of the LASSO-regularized Cox model reduces over-fitting [37].

The PHS290 described here has the strongest reported association with prostate cancer in men of European, African, and Asian genetic ancestry. The score was also associated with lifetime prostate-cancer-specific mortality in a population-based cohort. A performance gap remains between genetic ancestry groups that might be closed through development using more data from men of Asian or African ancestry. Nonetheless, the results here suggest PHS290 may improve prostate cancer risk-stratification efforts in multi-ancestry populations.

DATA AVAILABILITY

Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome (PRACTICAL) Consortium data are available upon request to the Data Access Committee (<http://practical.icr.ac.uk/blog>). Questions and requests for further information may be directed to PRACTICAL@icr.ac.uk. Code used for this work is stored in an institutional repository and will be shared upon request to the corresponding author.

REFERENCES

- Seibert TM, Fan CC, Wang Y, Zuber V, Karunamuni R, Parsons JK, et al. Polygenic hazard score to guide screening for aggressive prostate cancer: Development and validation in large scale cohorts. *BMJ*. 2018;360:1–7.
- Huynh-Le M-P, Fan CC, Karunamuni R, Thompson WK, Martinez ME, Eeles RA, et al. Polygenic hazard score is associated with prostate cancer in multi-ethnic populations. *Nat Commun*. 2021;12:1236.
- Callender T, Emberton M, Morris S, Pharoah PDP, Pashayan N. Benefit, Harm, and Cost-effectiveness Associated with Magnetic Resonance Imaging before Biopsy in Age-based and Risk-stratified Screening for Prostate Cancer. *JAMA Network Open*. 2021;4:2037657.
- Callender T, Emberton M, Morris S, Eeles R, Kote-Jarai Z, Pharoah PDP, et al. Polygenic risk-tailored screening for prostate cancer: A benefit-harm and cost-effectiveness modelling study. *PLoS Med*. 2019;16:e1002998.
- Petrovski S, Goldstein DB. Unequal representation of genetic variation across ancestry groups creates healthcare inequality in the application of precision medicine. *Genome Biol*. 2016;17. <https://doi.org/10.1186/s13059-016-1016-y>.
- Duncan L, Shen H, Gelaye B, Meijns J, Ressler K, Feldman M, et al. Analysis of polygenic risk score usage and performance in diverse human populations. *Nat Commun*. 2019;10. <https://doi.org/10.1038/s41467-019-11112-0>.
- Huynh-Le MP, Fan CC, Karunamuni R, Walsh EI, Turner EL, Athene Lane J, et al. A genetic risk score to personalize prostate cancer screening, applied to population data. *Cancer Epidemiol Biomark Preven*. 2020;29:1731–8.
- Karunamuni RA, Huynh-Le M-P, Fan CC, Thompson W, Eeles RA, Kote-Jarai Z, et al. Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer. *Prostate Cancer Prostatic Dis*. 2021. <https://doi.org/10.1038/s41391-020-00311-2>.
- Karunamuni RA, Huynh-Le M, Fan CC, Thompson W, Eeles RA, Kote-Jarai Z, et al. African-specific improvement of a polygenic hazard score for age at diagnosis of prostate cancer. *International Journal of Cancer*. 2021;148:99–105.
- Karunamuni RA, Huynh-Le M-P, Fan CC, Thompson W, Lui A, Martinez ME, et al. Performance of African-ancestry-specific polygenic hazard score varies according to local ancestry in 8q24. *Prostate Cancer Prostatic Dis*. 2021;1–9.
- Conti DV, Darst BF, Moss LC, Saunders EJ, Sheng X, Chou A, et al. Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. *Nat Genet*. 2021;53:65–75.
- Schumacher FR, Al Olama AA, Berndt SI, Benlloch S, Ahmed M, Saunders EJ, et al. Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. *Nat Genet*. 2018;50:928–36.
- Amos CI, Dennis J, Wang Z, Byun J, Schumacher FR, Gayther SA, et al. The OncoArray consortium: A network for understanding the genetic architecture of common cancers. *Cancer Epidemiol Biomark Preven*. 2017;26:126–35.
- Eeles RA, Olama AAA, Benlloch S, Saunders EJ, Leongamornlert DA, Tymrakiewicz M, et al. Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. *Nat Genet*. 2013;45:385–91.
- Karunamuni RA, Huynh-Le M-P, Fan CC, Eeles RA, Easton DF, Kote-Jarai ZS, et al. The effect of sample size on polygenic hazard models for prostate cancer. *Eur J Hum Genet*. 2020. <https://doi.org/10.1038/s41431-020-0664-2>.
- Huynh-Le M-P, Karunamuni R, Fan CC, Thompson WK, Muir K, Lophatananon A, et al. Common genetic and clinical risk factors: association with fatal prostate cancer in the Cohort of Swedish Men. *Prostate Cancer Prostatic Dis*. 2021;24:845–51.
- Discacciati A, Orsini N, Andersson S-O, Andren O, Johansson J-E, Mantzoros CS, et al. Coffee consumption and risk of localized, advanced and fatal prostate cancer: a population-based prospective study. *Annals of Oncology*. 2013;24:1912–8.
- Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, et al. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. *New England Journal of Medicine*. 2016;375:1415–24.
- Tibshirani R. The lasso method for variable selection in the cox model. *Stat Med*. 1997;16:385–95.
- Tibshirani R. Regression Shrinkage and Selection via the Lasso. *J R Stat Soc B*. 1996;58:267–88.
- Schaeffer E, Srinivas S, Antonarakis ES, Armstrong AJ, Bekelman JE, Cheng H, et al. Prostate cancer, version 1.2021: Featured updates to the nccn guidelines. *JNCCN*. 2021;19:134–43.
- Martin AR, Kanai M, Kamatani Y, Okada Y, Neale BM, Daly MJ. Clinical use of current polygenic risk scores may exacerbate health disparities. *Nat Genet*. 2019;51:584–91.
- Grinde KE, Qi Q, Thornton TA, Liu S, Shadyab AH, Chan KHK, et al. Generalizing polygenic risk scores from Europeans to Hispanics/Latinos. *Genet Epidemiol*. 2019;43:50–62.
- Popejoy AB, Fullerton SM. Genomics is failing on diversity. *Nature*. 2016;538:161–4.
- Riviere P, Luterstein E, Kumar A, Vitzthum LK, Deka R, Sarkar RR, et al. Survival of African American and non-Hispanic white men with prostate cancer in an equal-access health care system. *Cancer*. 2020;126:1683–90.

26. Dess RT, Hartman HE, Mahal BA, Soni PD, Jackson WC, Cooperberg MR, et al. Association of Black Race with Prostate Cancer-Specific and Other-Cause Mortality. *JAMA Oncol.* 2019;5:975–83.
27. Huynh-Le MP, Myklebust TÅ, Feng CH, Karunamuni R, Johannesen TB, Dale AM, et al. Age dependence of modern clinical risk groups for localized prostate cancer —A population-based study. *Cancer.* 2020;126:1691–9.
28. Brentnall AR, Cuzick J, Buist DSM, Bowles EJA. Long-term Accuracy of Breast Cancer Risk Assessment Combining Classic Risk Factors and Breast Density. *JAMA Oncol.* 2018;4:e180174.
29. Torkamani A, Wineinger NE, Topol EJ. The personal and clinical utility of polygenic risk scores. *Nat Rev Genet.* 2018;1.
30. Yeh H-C, Duncan BB, Schmidt MI, Wang N-Y, Brancati FL. Smoking, smoking cessation, and risk for type 2 diabetes mellitus: a cohort study. *Ann Intern Med.* 2010;152:10–17.
31. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Omland T, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. *N Engl J Med.* 2004;350:655–63.
32. Tsodikov A, Gulati R, Carvalho TM, de Heijnsdijk EAM, Hunter-Merrill RA, Mariotto AB, et al. Is prostate cancer different in black men? Answers from 3 natural history models. *Cancer.* 2017;123:2312–9.
33. Shi Z, Platz EA, Wei J, Na R, Fantus RJ, Wang C-H, et al. Performance of Three Inherited Risk Measures for Predicting Prostate Cancer Incidence and Mortality: A Population-based Prospective Analysis. *Eur Urol.* 2020. <https://doi.org/10.1016/j.eururo.2020.11.014>.
34. Carroll PR, Parsons JK, Box G, Carlsson S, Catalona WJ, Drake BF. National Comprehensive Cancer Network. Prostate Cancer Early Detection (Version 2.2021). https://www.nccn.org/professionals/physician_gls/pdf/prostate_detection.pdf Accessed October 10, 2021.
35. Giri VN, Knudsen KE, Kelly WK, Cheng HH, Cooney KA, Cookson MS, et al. Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. *JCO.* 2020. <https://doi.org/10.1200/JCO.20.00046>.
36. Hong H, Xu L, Liu J, Jones WD, Su Z, Ning B, et al. Technical Reproducibility of Genotyping SNP Arrays Used in Genome-Wide Association Studies. *PLOS ONE.* 2012;7:e44483.
37. McNeish DM. Using Lasso for Predictor Selection and to Assuage Overfitting: A Method Long Overlooked in Behavioral Sciences. *Multivariate Behav Res.* 2015;50:471–84.

AUTHOR CONTRIBUTIONS

All authors contributed to the study design and data collection. Analysis and manuscript preparation was performed by M-PH-L, RK, CCF, WKT, IGM, OAA, AMD, and TMS. All authors read and approved the final manuscript.

FUNDING

This study was funded in part by grants from the University of California (#C21CR2060), the United States National Institute of Health/National Institute of Biomedical Imaging and Bioengineering (#K08EB026503), the Prostate Cancer Foundation, the Research Council of Norway (#223273), KG Jebsen Stiftelsen, and South East Norway Health Authority. Funding for the PRACTICAL consortium member studies is detailed in the Supplementary Material. The content is solely the responsibility of the authors and does not necessarily represent the official views of any of the funding agencies, who had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

COMPETING INTERESTS

All authors declare no support from any organization for the submitted work except as follows: AMD and TMS report a past research grant from the US Department of Defense. OAA reports research grants from KG Jebsen Stiftelsen, Research Council of Norway, and South East Norway Health Authority. Authors declare no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years except as follows, with all of these relationships outside the present study: TMS reports honoraria from Multimodal Imaging Services Corporation, Varian Medical Systems, and WebMD; he has an equity interest in CorTechs Labs and also serves on its Scientific Advisory Board. These companies might potentially benefit from the research results. The terms of this arrangement have been reviewed and approved by the University of California San Diego in accordance with its conflict-of-interest policies. OAA reports speaker honoraria from Lundbeck. Authors declare no other relationships or activities that could appear to have influenced the submitted work except as follows: OAA has a patent application # U. S. 20150356243 pending; AMD also applied for this patent application and assigned it to UC San Diego. AMD has additional disclosures outside the present work: founder, equity holder, and advisory board member for CorTechs Labs, Inc.; founder and equity holder in HealthLytix, Inc., advisory board member of Human Longevity, Inc.; recipient of nonfinancial research support from General Electric Healthcare. OAA is a consultant for HealthLytix, Inc. Additional acknowledgments for the PRACTICAL consortium and contributing studies are described in the Supplementary Information.

ETHICS STATEMENT

The present analyses used de-identified data from the PRACTICAL consortium and have been approved by the Institutional Review Board at the University of California San Diego. All contributing studies were approved by the relevant ethics committees and performed in accordance with the Declaration of Helsinki.

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41391-022-00497-7>.

Correspondence and requests for materials should be addressed to Tyler M. Seibert.






Reprints and permission information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2022

Minh-Phuong Huynh-Le ^{1,2,3}, Roshan Karunamuni^{2,3}, Chun Chieh Fan ³, Lui Asona ², Wesley K. Thompson^{4,5}, Maria Elena Martinez⁶, Rosalind A. Eeles ^{7,8}, Zsofia Kote-Jarai⁷, Kenneth R. Muir ⁹, Artitaya Lophatananon⁹, Johanna Schleutker ^{10,11}, Nora Pashayan ^{12,13}, Jyotsna Batra ^{14,15}, Henrik Grönberg ¹⁶, David E. Neal ^{17,18,19}, Børge G. Nordestgaard ^{20,21}, Catherine M. Tangen²², Robert J. MacInnis^{23,24}, Alicja Wolk ²⁵, Demetrius Albanes²⁶, Christopher A. Haiman²⁷, Ruth C. Travis ²⁸, William J. Blot^{29,30}, Janet L. Stanford^{31,32}, Lorelei A. Mucci³³, Catharine M. L. West ³⁴, Sune F. Nielsen^{21,20}, Adam S. Kibel³⁵, Olivier Cussenot^{36,37}, Sonja I. Berndt²⁶, Stella Koutros²⁶, Karina Dalsgaard Sørensen ^{38,39}, Cezary Cybulski⁴⁰, Eli Marie Grindedal⁴¹, Florence Menegaux ⁴², Jong Y. Park ⁴³, Sue A. Ingles⁴⁴, Christiane Maier⁴⁵, Robert J. Hamilton^{46,47}, Barry S. Rosenstein⁴⁸, Yong-Jie Lu ⁴⁹, Stephen Watya⁵⁰, Ana Vega ^{51,52,53}, Manolis Kogevinas ^{54,55,56}, Fredrik Wiklund ¹⁶, Kathryn L. Penney⁵⁷, Chad D. Huff⁵⁸, Manuel R. Teixeira ^{59,60,61}, Luc Multigner ⁶², Robin J. Leach⁶³, Hermann Brenner ^{64,65,66}, Esther M. John⁶⁷, Radka Kaneva⁶⁸, Christopher J. Logothetis⁶⁹, Susan L. Neuhausen⁷⁰, Kim De Ruyck⁷¹, Piet Ost ⁷², Azad Razack⁷³, Lisa F. Newcomb^{31,74}, Jay H. Fowke ⁷⁵, Marija Gamulin ⁷⁶, Aswin Abraham ⁷⁷, Frank Claessens⁷⁸, Jose Esteban Castelao⁷⁹, Paul A. Townsend^{80,81}, Dana C. Crawford ⁸², Gyorgy Petrovics ^{83,84}

Ron H. N. van Schaik⁸⁵, Marie-Élise Parent^{86,87}, Jennifer J. Hu⁸⁸, Wei Zheng⁸⁹, UKGPCS collaborators⁹³, APCB (Australian Prostate Cancer BioResource)^{94,95}, NC-LA PCaP Investigators⁹⁶, The IMPACT Study Steering Committee and Collaborators⁹⁷, Canary PASS Investigators^{31,74}, The Profile Study Steering Committee⁹⁸, The PRACTICAL Consortium, Ian G. Mills⁸⁹, Ole A. Andreassen⁹⁰, Anders M. Dale^{91,3,90} and Tyler M. Seibert^{2,3,90,91,92✉}

¹Radiation Oncology, George Washington University, Washington, DC, USA. ²Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA, USA. ³Center for Multimodal Imaging and Genetics, University of California San Diego, La Jolla, CA, USA. ⁴Division of Biostatistics and Halicioğlu Data Science Institute, University of California San Diego, La Jolla, CA, USA. ⁵Department of Family Medicine and Public Health, University of California San Diego, La Jolla, CA, USA. ⁶University of California San Diego, Moores Cancer Center, Herbert Wertheim School of Public Health and Human Longevity Science, University of California San Diego, La Jolla, CA 92093-0012, USA. ⁷The Institute of Cancer Research, London SM2 5NG, UK. ⁸Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK. ⁹Division of Population Health, Health Services Research and Primary Care, University of Manchester, Oxford Road, Manchester M13 9PL, UK. ¹⁰Institute of Biomedicine, University of Turku, Turku, Finland. ¹¹Department of Medical Genetics, Genomics, Laboratory Division, Turku University Hospital, PO Box 52, 20521 Turku, Finland. ¹²Department of Applied Health Research, University College London, London WC1E 7HB, UK. ¹³Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Strangeways Laboratory, Worts Causeway, Cambridge CB1 8RN, UK. ¹⁴Australian Prostate Cancer Research Centre-Qld, Institute of Health and Biomedical Innovation and School of Biomedical Sciences, Queensland University of Technology, Brisbane, QLD 4059, Australia. ¹⁵Translational Research Institute, Brisbane, QLD 4102, Australia. ¹⁶Department of Medical Epidemiology and Biostatistics, Karolinska Institute, SE-171 77 Stockholm, Sweden. ¹⁷Nuffield Department of Surgical Sciences, University of Oxford, Room 6603, Level 6, John Radcliffe Hospital, Headley Way, Headington, Oxford OX3 9DU, UK. ¹⁸University of Cambridge, Department of Oncology, Box 279, Addenbrooke's Hospital, Hills Road, Cambridge CB2 0QQ, UK. ¹⁹Cancer Research UK, Cambridge Research Institute, Li Ka Shing Centre, Cambridge CB2 0RE, UK. ²⁰Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark. ²¹Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev 2200 Copenhagen, Denmark. ²²SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. ²³Cancer Epidemiology Division, Cancer Council Victoria, 615 St Kilda Road, Melbourne, VIC 3004, Australia. ²⁴Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Grattan Street, Parkville, VIC 3010, Australia. ²⁵Department of Surgical Sciences, Uppsala University, 75185 Uppsala, Sweden. ²⁶Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD 20892, USA. ²⁷Center for Genetic Epidemiology, Department of Preventive Medicine, Keck School of Medicine, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA 90015, USA. ²⁸Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford OX3 7LF, UK. ²⁹Division of Epidemiology, Department of Medicine, Vanderbilt University Medical Center, 2525 West End Avenue, Suite 800, Nashville, TN 37232, USA. ³⁰International Epidemiology Institute, Rockville, MD 20850, USA. ³¹Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98195, USA. ³²Department of Epidemiology, School of Public Health, University of Washington, Seattle, WA 98195, USA. ³³Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA 02115, USA. ³⁴Division of Cancer Sciences, University of Manchester, Manchester Academic Health Science Centre, Radiotherapy Related Research, The Christie Hospital NHS Foundation Trust, Manchester M13 9PL, UK. ³⁵Division of Urologic Surgery, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA. ³⁶Sorbonne Université, GRC n°5, AP-HP, Tenon Hospital, 4 rue de la Chine, F-45020 Paris, France. ³⁷CeRePP, Tenon Hospital, F-75020 Paris, France. ³⁸Department of Molecular Medicine, Aarhus University Hospital, Palle Juul-Jensen Boulevard 99, 8200 Aarhus N, Denmark. ³⁹Department of Clinical Medicine, Aarhus University, DK 8200 Aarhus N, Denmark. ⁴⁰International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, 70-115 Szczecin, Poland. ⁴¹Department of Medical Genetics, Oslo University Hospital, 0424 Oslo, Norway. ⁴²Exposome and Heredity, CESP (UMR 1018), Faculté de Médecine, Université Paris-Saclay, Inserm, Gustave Roussy, Villejuif, France. ⁴³Department of Cancer Epidemiology, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612, USA. ⁴⁴Department of Preventive Medicine, Keck School of Medicine, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA 90015, USA. ⁴⁵Humangenetik Tuebingen, Paul-Ehrlich-Str 23, D-72076 Tuebingen, Germany. ⁴⁶Dept. of Surgical Oncology, Princess Margaret Cancer Centre, Toronto, ON M5G 2M9, Canada. ⁴⁷Dept. of Surgery (Urology), University of Toronto, Toronto, Canada. ⁴⁸Department of Radiation Oncology and Department of Genetics and Genomic Sciences, Box 1236, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, USA. ⁴⁹Centre for Cancer Biomarker and Biotherapeutics, Barts Cancer Institute, Queen Mary University of London, John Vane Science Centre, Charterhouse Square, London EC1M 6BQ, UK. ⁵⁰Uro Care, Kampala, Uganda. ⁵¹Fundación Pública Galega Medicina Xenómica, Santiago de Compostela 15706, Spain. ⁵²Instituto de Investigación Sanitaria de Santiago de Compostela, Santiago De Compostela 15706, Spain. ⁵³Centro de Investigación en Red de Enfermedades Raras (CIBERER), Santiago De Compostela, Spain. ⁵⁴ISGlobal, Barcelona, Spain. ⁵⁵IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain. ⁵⁶Universitat Pompeu Fabra (UPF), Barcelona, Spain. ⁵⁷Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital/Harvard Medical School, Boston, MA 02115, USA. ⁵⁸Department of Epidemiology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA. ⁵⁹Department of Genetics, Portuguese Oncology Institute of Porto (IPO-Porto), 4200-072 Porto, Portugal. ⁶⁰Biomedical Sciences Institute (ICBAS), University of Porto, 4050-313 Porto, Portugal. ⁶¹Cancer Genetics Group, IPO-Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO-Porto), 4200-072 Porto, Portugal. ⁶²Univ Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, Rennes, France. ⁶³Department of Cell Systems and Anatomy, Mays Cancer Center, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA. ⁶⁴Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), D-69120 Heidelberg, Germany. ⁶⁵German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), D-69120 Heidelberg, Germany. ⁶⁶Division of Preventive Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Im Neuenheimer Feld 460, 69120 Heidelberg, Germany. ⁶⁷Departments of Epidemiology & Population Health and of Medicine, Division of Oncology, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94304, USA. ⁶⁸Molecular Medicine Center, Department of Medical Chemistry and Biochemistry, Medical University of Sofia, Sofia, 2 Zdrave Str., 1431 Sofia, Bulgaria. ⁶⁹The University of Texas M. D. Anderson Cancer Center, Department of Genitourinary Medical Oncology, 1515 Holcombe Blvd., Houston, TX 77030, USA. ⁷⁰Department of Population Sciences, Beckman Research Institute of the City of Hope, 1500 East Duarte Road, Duarte, CA 91010, USA. ⁷¹Ghent University, Faculty of Medicine and Health Sciences, Basic Medical Sciences, Proeftuinstraat 86, B-9000 Gent, Belgium. ⁷²Ghent University Hospital, Department of Radiotherapy, De Pintelaan 185, B-9000 Gent, Belgium. ⁷³Department of Surgery, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia. ⁷⁴Department of Urology, University of Washington, 1959 NE Pacific Street, Box 356510, Seattle, WA 98195, USA. ⁷⁵Division of Epidemiology, Department of Preventive Medicine, University of Tennessee Health Science Center, Memphis, TN 38163, USA. ⁷⁶Department of Oncology, University Hospital Centre Zagreb, University of Zagreb, School of Medicine, 10 000 Zagreb, Croatia. ⁷⁷Department of Oncology, Cross Cancer Institute, University of Alberta, 11560 University Avenue, Edmonton, AB T6G 1Z2, Canada. ⁷⁸Molecular Endocrinology Laboratory, Department of Cellular and Molecular Medicine, KU Leuven BE-3000, Belgium. ⁷⁹Genetic Oncology Unit, CHUVI Hospital, Complejo Hospitalario Universitario de Vigo, Instituto de Investigación Biomédica Galicia Sur (IISGS), 36204 Vigo (Pontevedra), Spain. ⁸⁰Division of Cancer Sciences, Manchester Cancer Research Centre, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, NIHR Manchester Biomedical Research Centre, Health Innovation Manchester, University of Manchester, Manchester M13 9WL, UK. ⁸¹The University of Surrey, Guildford, Surrey GU2 7XH, UK. ⁸²Case Western Reserve University, Department of Population and Quantitative Health Sciences, Cleveland Institute for Computational Biology, 2103 Cornell Road, Wolstein Research Building, Suite 2527, Cleveland, OH 44106, USA. ⁸³Uniformed Services University, 4301 Jones Bridge Rd, Bethesda, MD 20814, USA. ⁸⁴Center for Prostate Disease Research, 6720A Rockledge Drive, Suite 300, Bethesda, MD 20817, USA. ⁸⁵Department of Clinical Chemistry, Erasmus University Medical Center, 3015 CE Rotterdam, The Netherlands. ⁸⁶Epidemiology and Biostatistics Unit, Centre Armand-Frappier Santé Biotechnologie, Institut national de la recherche scientifique, 531 Boul. des Prairies, Laval, QC H7V 1B7, Canada. ⁸⁷Department of Social and Preventive Medicine, School of Public Health, University of Montreal, Montreal, QC, Canada. ⁸⁸The University of Miami School of Medicine, Sylvester Comprehensive Cancer Center, 1120 NW 14th Street, CRB 1511, Miami, FL 33136, USA. ⁸⁹Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK. ⁹⁰NORMENT, KG Jebsen Centre, Oslo University Hospital and University of Oslo, Oslo, Norway. ⁹¹Department of Radiology, University of California San Diego, La Jolla, CA, USA. ⁹²Department of Bioengineering, University of California San Diego, La Jolla, CA, USA. ⁹³<http://www.icr.ac.uk/our-research/research-divisions/division-of-genetics-and-epidemiology/oncogenetics/research-projects/ukgps/ukgps-collaborators>. ⁹⁴Australian Prostate Cancer Research Centre-Qld, Queensland University of Technology, Brisbane; Prostate Cancer Research Program, Monash University, Melbourne; Dame Roma Mitchell Cancer Centre, University of Adelaide, Adelaide; Chris O'Brien Lifehouse and The Kinghorn Cancer Centre, Sydney, NSW, Australia. ⁹⁵Translational Research Institute, Brisbane, QLD, Australia. ⁹⁶<https://pcap.bioinf.unc.edu/>. ⁹⁷<http://impact.icr.ac.uk>. ⁹⁸<http://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-study-find-out-looking-gene-changes-would-be-useful-in-screening-for-prostate-cancer-profile-pilot>. Members of the UKGPCS collaborators, APCB (Australian Prostate Cancer BioResource), NC-LA PCaP Investigators, The IMPACT Study Steering Committee and Collaborators, Canary PASS Investigators, The Profile Study Steering Committee, The PRACTICAL Consortium are listed in the Supplementary Information. [✉]email: seibert@ucsd.edu